HomeProductsBioactive CompoundsJAK/STAT SignalingFLT3Mivavotinib
Chemical structure of CAS 1312691-33-0

Mivavotinib

CAS No.1312691-33-0
MDL No.N/A
MFC17H21FN6O
MW344.40
InChI KeyMJHOMTRKVMKCNE-NWDGAFQWSA-N

Pricing & Availability

Pack SizePurityPriceAvailabilityAction
- -On RequestOn Request
Custom synthesis and bulk supply options are available upon request.

Product Information

CAS No.1312691-33-0
Product NameMivavotinib

Biological Targets

SYK

Associated Conditions

neoplasm·non-Hodgkins lymphoma·neoplasm of mature B-cells·hematopoietic and lymphoid system neoplasm·diffuse large B-cell lymphoma·
* The information provided here is compiled from public sources and is for reference only.

Related Articles

Studies related to this compound and its mechanism of action

The IUPHAR Guide to Immunopharmacology: connecting immunology and pharmacology.

Immunology • Vol. 160, Issue 1 • 2020
PMID: 32020584PMC: PMC7160657DOI: 10.1111/imm.13175

Inhibition of BCR signaling using the Syk inhibitor TAK-659 prevents stroma-mediated signaling in chronic lymphocytic leukemia cells.

Oncotarget • Vol. 8, Issue 1 • 2017
PMID: 27888629PMC: PMC5352193DOI: 10.18632/oncotarget.13557

Discovery of TAK-659 an orally available investigational inhibitor of Spleen Tyrosine Kinase (SYK).

Bioorganic & medicinal chemistry letters • Vol. 26, Issue 24 • 2016
PMID: 27839918DOI: 10.1016/j.bmcl.2016.10.087

Documentation